Elenae designs steric-blocking LNA ASO mixmers for disease-driving RNA biology across anti-miR, splice-modulating, exon-skipping, and selected protein-coding RNA applications. The platform combines AI-guided ASO design with broad extrahepatic pharmacology after simple subcutaneous dosing in saline.
Elenae is an extrahepatic LNA steric-blocking mixmer therapeutics company centered on AI-guided ASO design. The platform integrates target selection, steric-block ASO optimization, and tissue-access strategy to generate internal clinical programs and partnerable RNA medicine campaigns.
AI-guided LNA mixmer design that prioritizes small synthesis-ready libraries and has produced picomolar leads in prospective benchmarking. Spans anti-miR, splice modulation, exon-skipping, and translation-modulating applications. Prospective design benchmark: 2 of 9 designed molecules outperformed a reference ASO that took over a year and more than $1M of empirical screening.
Multi-omic, tissue-aware identification of disease-driving RNA nodes. Filters every candidate for steric-blockade druggability and for the tissue context the platform can reach.
Decision layer that determines where native SC exposure is sufficient and where local delivery or shuttle conjugation is required. Built on characterized LNA mixmer multi-tissue pharmacology.
Two distinct market signals frame this window.
One signal comes from oligonucleotide and tissue-access acquisitions. Cardior ($1.1B, Novo Nordisk) validated cardiac LNA mixmer chemistry. Regulus ($1.7B, Novartis) validated kidney miRNA. Avidity ($12B, Novartis) validated muscle-directed oligonucleotide delivery and late-stage neuromuscular RNA therapeutics.
A second signal comes specifically from AI-guided oligonucleotide design. Lilly's collaboration with Creyon Bio (multi-target deal potentially exceeding $1B) signaled pharma interest in AI-native ASO platforms. Adjacent pharma moves in AI-enabled drug discovery more broadly, such as AstraZeneca's $555M Algen collaboration in functional genomics, reinforce the same underlying thesis.
Elenae sits at the intersection of these signals: extrahepatic LNA mixmer chemistry combined with a working AI-guided design engine and a prospective design benchmark on a defined target.
See how the platform unifies these capabilities →Presented the platform story at UC Irvine.
Scored 25 (high consensus) for the anti-miR-128 heart failure program. Funding decision pending.
Former Partner at The Column Group. Brings deep biotech venture and board experience.